Pregnant women with autoimmune rheumatic diseases, especially systemic lupus erythematosus (SLE) and systemic sclerosis, are at high risk of maternal disease flares, adverse fetal outcomes and potential drug teratogenic effects, making the management of these women particularly challenging. With improvements in diagnosis and treatment, however, these risks can be minimized by appropriate timing...
